BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 25788269)

  • 21. Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.
    Quotti Tubi L; Canovas Nunes S; Brancalion A; Doriguzzi Breatta E; Manni S; Mandato E; Zaffino F; Macaccaro P; Carrino M; Gianesin K; Trentin L; Binotto G; Zambello R; Semenzato G; Gurrieri C; Piazza F
    Leukemia; 2017 Feb; 31(2):292-300. PubMed ID: 27479180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dysregulated expressions of PTEN, NF-κB, WWP2, p53 and c-Myc in different subtypes of B cell lymphoma and reactive follicular hyperplasia.
    Fu H; Jin C; Zhu Q; Liu T; Ke B; Li A; Zhang T
    Am J Transl Res; 2019; 11(2):1092-1101. PubMed ID: 30899409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Syk-dependent mTOR activation in follicular lymphoma cells.
    Leseux L; Hamdi SM; Al Saati T; Capilla F; Recher C; Laurent G; Bezombes C
    Blood; 2006 Dec; 108(13):4156-62. PubMed ID: 16912221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
    Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
    J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas.
    Dogan A; Bagdi E; Munson P; Isaacson PG
    Am J Surg Pathol; 2000 Jun; 24(6):846-52. PubMed ID: 10843287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
    Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
    J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
    Bujisic B; De Gassart A; Tallant R; Demaria O; Zaffalon L; Chelbi S; Gilliet M; Bertoni F; Martinon F
    Blood; 2017 Apr; 129(17):2420-2428. PubMed ID: 28167662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
    Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
    BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylation changes of SIRT1, KLF4, DAPK1 and SPG20 in B-lymphocytes derived from follicular and diffuse large B-cell lymphoma.
    Frazzi R; Zanetti E; Pistoni M; Tamagnini I; Valli R; Braglia L; Merli F
    Leuk Res; 2017 Jun; 57():89-96. PubMed ID: 28324774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
    van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
    PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression analysis in aggressive NHL.
    Chan WC; Huang JZ
    Ann Hematol; 2001; 80 Suppl 3():B38-41. PubMed ID: 11757704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BAFF-R is expressed on B-cell lymphomas depending on their origin, and is related to proliferation index of nodal diffuse large B-cell lymphomas.
    Takahata H; Ohara N; Ichimura K; Tanaka T; Sato Y; Morito T; Takata K; Kojima M; Kobata T; Yoshino T
    J Clin Exp Hematop; 2010; 50(2):121-7. PubMed ID: 21123970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
    Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
    Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity.
    Lossos IS; Levy R; Alizadeh AA
    Leukemia; 2004 Nov; 18(11):1775-9. PubMed ID: 15385936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
    Lu X; Nechushtan H; Ding F; Rosado MF; Singal R; Alizadeh AA; Lossos IS
    Blood; 2005 Apr; 105(7):2924-32. PubMed ID: 15591113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells.
    Wińska P; Widło Ł; Skierka K; Krzyśko A; Koronkiewicz M; Cieśla JM; Cieśla J; Bretner M
    Anticancer Res; 2019 Jul; 39(7):3531-3542. PubMed ID: 31262877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
    Bellan C; Stefano L; Giulia de F; Rogena EA; Lorenzo L
    Hematol Oncol; 2010 Jun; 28(2):53-6. PubMed ID: 19844983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
    Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
    Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.